Wednesday, July 8, 2026

pharma · Facioscapulohumeral Muscular Dystrophy (FSHD) · Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) · FULC

Fulcrum Therapeutics

Fulcrum Therapeutics clinical programs — 12 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

26 Landsdowne St, Cambridge, Massachusetts 02139, US HQ
2016 Founded
73 Employees
Public company Type
FULC · NYSE Ticker
Company details
Intelligence · Clinical Programs

Fulcrum Therapeutics projects

12 ClinicalTrials.gov programs sponsored by Fulcrum Therapeutics.

Fulcrum Therapeutics has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 1821-FSH-301

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule active

    1 trial
  2. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 3 small molecule terminated

    2 trials
  3. Losmapimod oral tablet

    Fulcrum Therapeutics

    COVID-19

    phase 3 small molecule terminated

    1 trial
  4. ACE393

    Fulcrum Therapeutics

    Campylobacter Infection

    phase 2 mab active

    1 trial
  5. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy 1

    phase 2 small molecule terminated

    1 trial
  6. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

    phase 2 small molecule active

    1 trial
  7. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

    phase 2 small molecule active

    1 trial
  8. Losmapimod oral tablet

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 2 small molecule completed

    1 trial
  9. Pociredir

    Fulcrum Therapeutics

    Sickle Cell Disease

    phase 2 small molecule active

    2 trials
  10. FTX-6058/placebo oral capsule(s)

    Fulcrum Therapeutics

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial
  11. Losmapimod 15 mg oral tablet

    Fulcrum Therapeutics

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial
  12. Pociredir oral capsule(s)

    Fulcrum Therapeutics

    Sickle Cell Disease

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Fulcrum Therapeutics have?

12 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.